PLK1 and malignant colon neoplasm: PLK1 inhibitors also synergistically with mTOR inhibitors to compensatively induce MYC expression, overcome the oxaliplatin resistance of colon cancer, and enhance the radiosensitivity of medulloblastoma (6, 45, 46).